Trillium Therapeutics (NASDAQ:TRIL) has priced its public offering of 35,731,818 common shares and 1,250,000 Series II Non-Voting Convertible First Preferred Shares, both at $2.75 per share, for expected gross proceeds of $101.7M.
Underwriters' over-allotment is an additional 5,547,272 common shares.
Net proceeds will be used for clinical development of CD47 programs, research, manufacturing and regulatory activities, and working capital and general corporate purposes.
Closing date is January 28.
Shares are up 5% premarket.
News 
Market Data 
Discover 
